search
Back to results

Spondylolisthesis Treated With an iO-Flex® System Enabled Decompression (STRiDE)

Primary Purpose

Radiculopathy, Spondylolisthesis, Lumbar Spinal Stenosis

Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Decompression using the iO-Flex® system
Sponsored by
Baxano Surgical, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Radiculopathy focused on measuring spondylolisthesis, lumbar spinal stenosis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Adult (> 18 years of age)
  2. Leg/buttock pain, with or without back pain
  3. Grade 1 degenerative spondylolisthesis (≤25% slippage)
  4. NRS pain score for leg pain of 4/10 or greater
  5. ODI score of 30/100 or greater
  6. Failed non-operative medical management for a period of at least 6 months
  7. Confirmed clinical diagnosis of lumbar spinal stenosis
  8. Confirmation of central and/or lateral recess stenosis with or without foraminal stenosis, at one level or at two adjacent levels from L2-S1, with concordant symptoms. Subjects with central and/or lateral recess stenosis and spondylolisthesis at one level, may have symptomatic central, lateral recess or foraminal stenosis treated at one adjacent level. A "below-the pedicle" pass to decompress a third segment can be completed provided laminotomies are performed at no more than 2 levels. Subjects that, following an intraoperative decision, have a 3-level laminotomy and decompression will not be considered enrolled. Confirmation of spinal stenosis is shown on MRI or CT scan with evidence of nerve root impingement (displacement or compression) by either osseous or non-osseous elements.
  9. Ability to give voluntary, written informed consent to participate in this clinical investigation and ability to participate in follow up examinations and complete patient questionnaires

Exclusion Criteria:

  1. Back pain only
  2. Diagnosis of moderate to severe peripheral neuropathy such as diabetic or idiopathic peripheral neuropathy, by EMG/NCS or a Neurologist.
  3. History of pathologic fractures of the vertebrae
  4. Primary disc pathology; planned or incidental discectomies will NOT be excluded as long as surgeon believes the disc pathology is not the primary reason for the surgical intervention.
  5. Subjects for whom removal of the midline structures is planned, likely or is the result of an intraoperative decision; every attempt should be made to spare the supraspinous, interspinous and facet capsular ligaments.
  6. Significant instability of the lumbar spine as defined by ≥ 4mm translational motion between standing lateral view flexion and extension radiographs
  7. Prior surgery of the lumbar spine
  8. Spondylolisthesis greater than grade 1 (on a scale of 1 to 4)
  9. Spondylolysis (pars fracture) at any level in the lumbar spine
  10. Degenerative lumbar scoliosis with a Cobb angle of ≥ 25°
  11. Vascular claudication in the lower extremities
  12. Cauda equina syndrome
  13. Evidence of active (systemic or local) infection at time of surgery
  14. Paget's disease at involved segment or metastasis to the vertebra, osteomalacia, or other metabolic bone disease
  15. Tumor in the spine or a malignant tumor except for basal cell carcinoma.
  16. Prisoner or transient
  17. Any significant psychological disturbance past or present, psychotic or neurotic that could impair the consent process or ability to complete subject self-report questionnaires
  18. Involved in pending litigation of the spine or worker's compensation related to the back
  19. Inability to communicate clearly in the English language
  20. Morbid obesity (BMI > 40)
  21. Pregnant, nursing, or planning on becoming pregnant.
  22. History of narcotic abuse
  23. Current involvement in another drug or device clinical trial
  24. Uncontrolled diabetes
  25. Irreversible coagulopathy or bleeding disorder (patients on anticoagulant therapy may participate. Investigators should follow routine practices for perioperative discontinuation and reinitiation of anticoagulants.)
  26. Plans to relocate in the next 2 years
  27. Subject unwilling to undergo a blood transfusion, if necessary

Sites / Locations

  • Eden Medical Center
  • Olympia Medical Center
  • Orange County Neurological Associates
  • University California Irvine
  • Southern California Orthopedic Institute
  • Georgetown University
  • Medical Center of Trinity
  • Florida Orthopaedic Institute
  • Resurgens Orthopaedics
  • Suburban Orthopedics
  • Indiana Spine Group
  • Scott and White Memorial Hospital
  • VCU Medical Center
  • Tuckahoe Orthopedics

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Surgery

Arm Description

Decompression using the iO-Flex® system

Outcomes

Primary Outcome Measures

Oswestry Disability Index (ODI)
Responder analysis

Secondary Outcome Measures

Operative success
Achieving intended decompression using the iO-Flex® System. The number of neural foramen in which the iO-Flex® System was used for decompression compared to the number in which an attempt was made but not completed.
Oswestry Disability Index (ODI)
Responder analysis
Oswestry Disability Index (ODI)
Comparison of ODI scores between baseline and each of the following follow-up visits: 6, 12, 24, 36, 48, and 60 month visits
Numerical Rating Scale (NRS)
Comparison of NRS scores for back and leg pain between baseline and each of the following follow-up visits: 6, 12, 24, 36, 48, and 60 month visits
Zurich Claudication Questionnaire (ZCQ)
Comparison of ZCQ scores between baseline and each of the following follow-up visits: 6, 12, 24, 36, 48, and 60 month visits
SF-36 Health Survey
Comparison of SF-36 scores between baseline and each of the following follow-up visits: 6, 12, 24, 36, 48, and 60 month visits
Treatment survival rate
To characterize longevity of the treatment effect of a decompression using the iO-Flex® System.

Full Information

First Posted
April 18, 2011
Last Updated
April 21, 2014
Sponsor
Baxano Surgical, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT01338766
Brief Title
Spondylolisthesis Treated With an iO-Flex® System Enabled Decompression
Acronym
STRiDE
Official Title
Spondylolisthesis Treated With an iO-Flex® System Enabled Decompression (STRiDE)
Study Type
Interventional

2. Study Status

Record Verification Date
April 2014
Overall Recruitment Status
Unknown status
Study Start Date
April 2011 (undefined)
Primary Completion Date
December 2014 (Anticipated)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Baxano Surgical, Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the clinical performance of a decompression using the FDA cleared iO-Flex® System on-label in treating patients with spinal stenosis and stable grade I degenerative lumbar spondylolisthesis using a precision estimate assuming a 55% positive response rate.
Detailed Description
This is a prospective, non-randomized, multi-center (up to 30 sites) controlled clinical study enrolling 100 subjects following a pre-specified protocol with no site enrolling more than 30 subjects. All eligible subjects providing written informed consent and meeting study eligibility criteria will receive a facet preserving decompression using the FDA cleared iO-Flex® system on label. Treatment success using the iO-Flex® System will be analyzed using a precision estimate assuming a 55% positive response rate. In addition to baseline characteristics and procedural parameters, subject outcomes will be assessed at 6 weeks, 6-, 12-, and 24 months. The study will have an extended follow-up phase with annual follow-up contact through 5 years to evaluate retreatment for the original indication at these late time points.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Radiculopathy, Spondylolisthesis, Lumbar Spinal Stenosis
Keywords
spondylolisthesis, lumbar spinal stenosis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Surgery
Arm Type
Experimental
Arm Description
Decompression using the iO-Flex® system
Intervention Type
Procedure
Intervention Name(s)
Decompression using the iO-Flex® system
Intervention Description
Decompression using the iO-Flex® system
Primary Outcome Measure Information:
Title
Oswestry Disability Index (ODI)
Description
Responder analysis
Time Frame
24 Months
Secondary Outcome Measure Information:
Title
Operative success
Description
Achieving intended decompression using the iO-Flex® System. The number of neural foramen in which the iO-Flex® System was used for decompression compared to the number in which an attempt was made but not completed.
Time Frame
Operative (day 1)
Title
Oswestry Disability Index (ODI)
Description
Responder analysis
Time Frame
6, 12, 36, 48 and 60 months
Title
Oswestry Disability Index (ODI)
Description
Comparison of ODI scores between baseline and each of the following follow-up visits: 6, 12, 24, 36, 48, and 60 month visits
Time Frame
6, 12, 24, 36, 48 and 60 months
Title
Numerical Rating Scale (NRS)
Description
Comparison of NRS scores for back and leg pain between baseline and each of the following follow-up visits: 6, 12, 24, 36, 48, and 60 month visits
Time Frame
6, 12, 24, 36, 48 and 60 months
Title
Zurich Claudication Questionnaire (ZCQ)
Description
Comparison of ZCQ scores between baseline and each of the following follow-up visits: 6, 12, 24, 36, 48, and 60 month visits
Time Frame
6, 12, 24, 36, 48 and 60 months
Title
SF-36 Health Survey
Description
Comparison of SF-36 scores between baseline and each of the following follow-up visits: 6, 12, 24, 36, 48, and 60 month visits
Time Frame
6, 12, 24, 36, 48 and 60 months
Title
Treatment survival rate
Description
To characterize longevity of the treatment effect of a decompression using the iO-Flex® System.
Time Frame
Ongoing out to 60 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult (> 18 years of age) Leg/buttock pain, with or without back pain Grade 1 degenerative spondylolisthesis (≤25% slippage) NRS pain score for leg pain of 4/10 or greater ODI score of 30/100 or greater Failed non-operative medical management for a period of at least 6 months Confirmed clinical diagnosis of lumbar spinal stenosis Confirmation of central and/or lateral recess stenosis with or without foraminal stenosis, at one level or at two adjacent levels from L2-S1, with concordant symptoms. Subjects with central and/or lateral recess stenosis and spondylolisthesis at one level, may have symptomatic central, lateral recess or foraminal stenosis treated at one adjacent level. A "below-the pedicle" pass to decompress a third segment can be completed provided laminotomies are performed at no more than 2 levels. Subjects that, following an intraoperative decision, have a 3-level laminotomy and decompression will not be considered enrolled. Confirmation of spinal stenosis is shown on MRI or CT scan with evidence of nerve root impingement (displacement or compression) by either osseous or non-osseous elements. Ability to give voluntary, written informed consent to participate in this clinical investigation and ability to participate in follow up examinations and complete patient questionnaires Exclusion Criteria: Back pain only Diagnosis of moderate to severe peripheral neuropathy such as diabetic or idiopathic peripheral neuropathy, by EMG/NCS or a Neurologist. History of pathologic fractures of the vertebrae Primary disc pathology; planned or incidental discectomies will NOT be excluded as long as surgeon believes the disc pathology is not the primary reason for the surgical intervention. Subjects for whom removal of the midline structures is planned, likely or is the result of an intraoperative decision; every attempt should be made to spare the supraspinous, interspinous and facet capsular ligaments. Significant instability of the lumbar spine as defined by ≥ 4mm translational motion between standing lateral view flexion and extension radiographs Prior surgery of the lumbar spine Spondylolisthesis greater than grade 1 (on a scale of 1 to 4) Spondylolysis (pars fracture) at any level in the lumbar spine Degenerative lumbar scoliosis with a Cobb angle of ≥ 25° Vascular claudication in the lower extremities Cauda equina syndrome Evidence of active (systemic or local) infection at time of surgery Paget's disease at involved segment or metastasis to the vertebra, osteomalacia, or other metabolic bone disease Tumor in the spine or a malignant tumor except for basal cell carcinoma. Prisoner or transient Any significant psychological disturbance past or present, psychotic or neurotic that could impair the consent process or ability to complete subject self-report questionnaires Involved in pending litigation of the spine or worker's compensation related to the back Inability to communicate clearly in the English language Morbid obesity (BMI > 40) Pregnant, nursing, or planning on becoming pregnant. History of narcotic abuse Current involvement in another drug or device clinical trial Uncontrolled diabetes Irreversible coagulopathy or bleeding disorder (patients on anticoagulant therapy may participate. Investigators should follow routine practices for perioperative discontinuation and reinitiation of anticoagulants.) Plans to relocate in the next 2 years Subject unwilling to undergo a blood transfusion, if necessary
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sylvain Palmer, M.D.
Organizational Affiliation
Neurological Surgery Medical Associates
Official's Role
Principal Investigator
Facility Information:
Facility Name
Eden Medical Center
City
Castro Valley
State/Province
California
ZIP/Postal Code
94546
Country
United States
Facility Name
Olympia Medical Center
City
Los Angeles
State/Province
California
ZIP/Postal Code
90036
Country
United States
Facility Name
Orange County Neurological Associates
City
Mission Viejo
State/Province
California
ZIP/Postal Code
92691
Country
United States
Facility Name
University California Irvine
City
Orange
State/Province
California
ZIP/Postal Code
92868
Country
United States
Facility Name
Southern California Orthopedic Institute
City
Van Nuys
State/Province
California
ZIP/Postal Code
91405
Country
United States
Facility Name
Georgetown University
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20057
Country
United States
Facility Name
Medical Center of Trinity
City
Odessa
State/Province
Florida
ZIP/Postal Code
33556
Country
United States
Facility Name
Florida Orthopaedic Institute
City
Temple Terrace
State/Province
Florida
ZIP/Postal Code
33637
Country
United States
Facility Name
Resurgens Orthopaedics
City
Cumming
State/Province
Georgia
ZIP/Postal Code
30041
Country
United States
Facility Name
Suburban Orthopedics
City
Bartlett
State/Province
Illinois
ZIP/Postal Code
60103
Country
United States
Facility Name
Indiana Spine Group
City
Carmel
State/Province
Indiana
ZIP/Postal Code
46032
Country
United States
Facility Name
Scott and White Memorial Hospital
City
Temple
State/Province
Texas
ZIP/Postal Code
76508
Country
United States
Facility Name
VCU Medical Center
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23219
Country
United States
Facility Name
Tuckahoe Orthopedics
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23226
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Spondylolisthesis Treated With an iO-Flex® System Enabled Decompression

We'll reach out to this number within 24 hrs